M. Pettoellomantovani et al., PROSPECTIVE-STUDY OF LACTASE ABSORPTION DURING CANCER-CHEMOTHERAPY - FEASIBILITY OF A YOGURT-SUPPLEMENTED DIET IN LACTOSE MALABSORBERS, Journal of pediatric gastroenterology and nutrition, 20(2), 1995, pp. 189-195
Chemotherapy is a recognized cause of morphological alterations to the
proximal intestine. Lactose malabsorption, the functional consequence
of a small intestinal enzymatic derangement, has been shown to play a
n important role in causing gastrointestinal symptoms in subjects rece
iving chemotherapy. To establish a rational basis for the exclusion of
lactose from the diet and to reduce the risk of developing gastrointe
stinal symptoms, we conducted a study of lactose absorption in 20 chil
dren during cancer chemotherapy. Because lactose is an important nutri
tional sugar, the tolerance of lactose provided by yogurt was examined
. Lactose absorption was investigated by a hydrogen breath test (BT) a
fter oral ingestion of milk (250 ml) containing physiological doses of
lactose (12 g). The effect of yogurt supplementation was also tested
by BT after meals of yogurt (450 g) also containing physiological dose
s of lactose (12.1 g). In 11 children, lactose malabsorption was detec
ted by BT during the study before any gastrointestinal symptom reveale
d this status. Of these 11 children, no gastrointestinal discomfort de
veloped in five receiving a lactose-excluded diet. In contrast, in the
six children not restricted in lactose intake, gastrointestinal sympt
oms were observed 4 to 13 weeks after lactose malabsorption was detect
ed by BT. The findings of our study suggested the usefulness of dietar
y supplementation with yogurt, a lactose-containing food, in children
who developed lactose malabsorption. In fact, all lactose-malabsorbent
children showed good lactose absorption and tolerance when tested by
yogurt BT. Furthermore, a yogurt-supplemented diet was also successful
in three subjects initially recognized as lactose intolerant. In conc
lusion, the data presented have important implications in reducing the
risk of developing gastrointestinal symptoms in children receiving ca
ncer chemotherapy.